18 and older, any sex, with Atrial Fibrillation, Persistent or Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Number of Participants With Acute Procedure SuccessPrimary· During the procedure
Acute Procedure Success is defined as targeting and successful elimination of significant sources of electrographic flow (EGF) through radiofrequency ablation. EGF-identified sources are significant when their leading source activity is ≥ 26%. Successful elimination is defined as reduction of the source activity of the leading source to \<26% upon post-ablation remapping using EGF mapping.
Group
Value
95% CI
Subjects With EGF Identified Sources
13
Number of Participants With 12-month Freedom From AF RecurrenceSecondary· 90 day - 12 months
This measure represents the number of subjects with freedom from documented episodes of atrial fibrillation (AF) recurrence lasting longer than 30 seconds from the 90-day post-procedure blanking period through 12 months of follow-up.
Only subjects with completed 12 month follow-up are included in this analysis.
Group
Value
95% CI
Subjects That Received EGF-guided Ablation
8
Subjects That Did Not Receive EGF-guided Ablation
6
Adverse events — posted to ClinicalTrials.gov
Time frame: From Index Procedure to 12 Month Follow Up.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Subjects That Received EGF-guided Ablation
Serious: 0/13 (0%)
Deaths: 0/13
Subjects That Did Not Receive EGF-guided Ablation
Serious: 1/12 (8%)
Deaths: 0/12
Serious adverse events (1 terms)
Reaction
System
Subjects That Received EGF…
Subjects That Did Not Rece…
Hemorrhage of iliac vein with retroperitoneal hematoma
This post-market global registry will evaluate the ability of Electrographic Flow (EGF™) mapping to identify atrial fibrillation (AF) sources and guide ablation therapy in patients with atrial fibrillation in real-world setting.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Atrial Fibrillation, Persistent
Currently open trials in the same condition.
NCT06833138 — Atrioventricular Node Ablation and Conduction System Pacing in Patients With Well Controlled Permanent Atrial Fibrillati
· NA
· recruiting
NCT06654401 — Electrical Cardioversion As a Predictor in Postoperative Preservation of Sinus Rhythm
· NA
· recruiting
NCT06578793 — Comparison of Catheter Plus Marshall Vein Ablation vs. Catheter Ablation Alone in Persistent AF With Heart Failure
· NA
· recruiting
NCT06249347 — Left Roof Linear, Mitral Isthmus Linear and Left Anterior Septal Linear Ablation for Non-paroxysmal AF: PROMISED Trial.
· NA
· recruiting
NCT06172699 — Assert-IQ Implantable Cardiac Monitor (ICM) Post Market Study
· active not recruiting
Other Ablacon, Inc. trials
Trials by the same sponsor.
NCT06260670 — FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation
· NA
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ablacon, Inc.
Last refreshed: 10 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05481359.